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Infectious agents come in many forms, but they have been grouped into five distinct classes of
agents: viruses, bacteria, fungi, parasites, and prions. Cancer is not normally on this list. Infec-
tious agents like Human papilloma virus (HPV) or Human T-lymphotropic virus type 1
(HTLV-1) can cause cancers in infected hosts, but these cancers are generated within each new
individual from oncogenic changes within the hosts’ own cells, and they stay within that indi-
vidual. If cancer cells did travel from one individual to another, a normal immune system
would be able to recognize them as foreign and reject them. Cancer is thus usually a self-limit-
ing disease—it either regresses or it kills its host, and the death of the host marks the death of
the cancer lineage.
But this is not always the case. Transmissible cancers have been identified as spreading
within two vertebrates, dogs (Canis lupus familiaris) and Tasmanian devils (Sarcophilus harri-
sii), and more recently, multiple independent lineages of transmissible cancer have been found
in four species of bivalves (Fig 1). This is an infectiousmodality that has significant effects on
animals in both the terrestrial and marine environments, as well as in both vertebrates and
invertebrates. While large-scale transmission of cancer has not been observed in humans,
transmission between humans has been observedon a small scale in a number of circum-
stances, often in the context of immune suppression. With more research, more cases are likely
to be found in humans as well as other animals.
Canine Transmissible Venereal Tumor
The first transmissible cancer to be identifiedwas canine transmissible venereal tumor
(CTVT), a solid tumor that spreads within populations of dogs through sexual contact. This
was identified as a transmissible disease and was first experimentally transplanted from dog to
dog in 1876 [1]. The etiology of the disease was initially uncertain, but many successful trans-
plant experiments, common karyotypic rearrangements [2], and the finding of a unique inte-
gration of a LINE1 retrotransposon in front of the c-myc gene in all cases of CTVT [3]
suggested that transmission occurs through transfer and replication of the cancer cells them-
selves, rather than through viral modification of cells in each new host. Analysis of dog leuko-
cyte antigen alleles, polymorphicmicrosatellite loci, and mitochondrial DNA confirmed that
this cancer is spread as a clonal transmissible cancer lineage [4,5]. Another unexpected feature
of CTVT is that it has repeatedly acquired newmitochondrial genomes from its hosts through-
out its evolution [6,7]. This suggests that asexual replication of cancer cells may lead to a
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Muller’s ratchet [8] process in mitochondria, where accumulation of mutations make cancers
unsustainable in the long term without reintroduction of competent mitochondrial genomes.
CTVT spreads as a sexually transmitted infection in feral dog populations throughout the
world, infecting animals in at least 90 countries on all continents except Antarctica [9]. An
analysis of the CTVTgenome concluded that the cells have been spreading as a transmissible
cancer lineage for 10,000–12,000 years and likely arose from an early dog most closely related
to Alaskan malamutes [10]. While experimentally transplanted CTVTusually regresses after a
fewmonths, naturally acquired disease does not always regress [2]. Thus, these cells have been
evolving and spreading as an asexual parasitic organism that has outlived its original canine
host by more than 500 generations.
Tasmanian Devil Facial Tumor Disease
The first observation of a Tasmanian devil suffering from devil facial tumor disease (DFTD)
was in 1996 [11]. DFTD is a solid facial tumor that spreads from animal to animal through
physical contact when devils bite each other. It was identified as a transmissible cancer when a
unique karyotypic rearrangement was found in tumors of multiple animals [12] and was con-
firmed after sequencing of the genomes of two isolates of DFTD [13]. The fatal disease contin-
ues to spread through the devil population and threatens them with extinction, although
sequestered insurance populations and ongoing research on possible treatments may help
maintain the species [14].
In a recent report, a second, apparently completely independent, lineage of DFTD (termed
DFT2) was identified in a small number of animals, suggesting that if the conditions allow,
transmissible cancers may arise multiple times [15]. Interestingly, the first lineage of DFTD
Fig 1. Comparison of the known lineages of infectious cancers in natural populations.
doi:10.1371/journal.ppat.1005904.g001
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identified (now termedDFT1) arose from a female devil, but DFT2 arose from a male. The
first five cases of DFT2 were found in males, so it is possible that females have some ability to
recognize the male DFT2 cells as nonself, but the numbers of cases currently reported are too
low to confirm this.
Bivalve Transmissible Neoplasias
Fatal leukemia-like neoplasias, called disseminated neoplasia or hemic neoplasia, have been
reported in at least 15 different bivalve species [16,17]. They can occur at stable enzootic levels,
but several epizootic events have been reported, including an outbreak of disease in soft-shell
clams (Mya arenaria) on Prince Edward Island, Canada, where prevalences of>90% were
recorded, and massive population loss was observed [17,18]. Analysis of the neoplastic cells in
soft-shell clams revealed a dramatic amplification in the copy number of a retrotransposon
[19], with identical integration sites in neoplastic cells frommultiple animals. These data,
along with analysis of microsatellites and mitochondrial DNA SNPs, showed that the etiologic
agent of this disease is the neoplastic cell itself, as with CTVT and DFTD [20].
The finding of transmissible cancer in soft-shell clams and some evidence from dissemi-
nated neoplasia in mussels [21,22] suggested that the neoplasias of other bivalves could also be
transmissible. Recently, disseminated neoplasia was analyzed from three additional bivalve
species (the mussel,Mytilus trossulus; the cockle,Cerastoderma edule; and the golden carpet-
shell clam, Polititapes aureus), and independent transmissible cancer cell lineages were
observed in each species [23]. In both mussels and cockles, the cancer lineages arose from the
corresponding host species, and in cockles, two apparently independent cockle-derivedcancer
lineages were found to be spreading through the population, as was found in Tasmanian devils.
More unexpectedly, the cancer observed in P. aureus was found to be the result of a cross-spe-
cies transmission, derived from a different, but related, species,Venerupis corrugata. Curiously,
V. corrugata itself does not have a high incidence of the disease, despite living in the same area
as P. aureus. As multiple lineages of transmissible cancers are spreading throughmultiple
bivalve species, we call these diseases bivalve transmissible neoplasias (BTN). Since cancers
from four bivalve species have been analyzed for transmissible cancer and all four were attrib-
utable to BTN lineages, it is reasonable to predict that disseminated neoplasia in other bivalves
will be found to be due to BTN as well.
Transmissible Cancers in Humans
Transmission of cancer from person to person is exceedingly rare. Any cancer cells that some-
how find their way from a donor to a recipient would normally be recognized as foreign and
rejected by a functional immune system. However, human-to-human transmission of cancer
has been reported in several special settings [24], including transplant recipients acquiring can-
cer from tissue donors [25,26] and transfer of cancer frommother to fetus [27]. In a recent,
remarkable case of immune suppression leading to transmission of cancer cells, an AIDS
patient acquired neoplastic cells that derived from the cells of a dwarf tapeworm [28]. These
are extreme cases in which both physical barriers and immune barriers are lowered.
Only a few cases of human cancer transmission without immune suppression or partially
matched cells have been reported. There has been a case of a surgeon who accidentally intro-
duced a cancer into his own hand during surgery [29], and at least one case of a needlestick
accident leading to growth of a small nodule derived from a human adenocarcinoma cell line
in an immunocompetent researcher [30]. In both cases, the tumors were excised and did not
recur.
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Immune Responses to Contagious Cancer
In conventional cancers, the cancer cells must avoid recognition of neoantigens made by
abnormal induction or mutation of host genes, but contagious cancers must also avoid recogni-
tion as cells from a foreign individual. The Major Histocompatibility Complex (MHC) genes in
jawed vertebrates form a very strong (but not insurmountable) barrier to cancer allografts.
Indeed, CTVT is known to down-regulate expression of MHC genes [31] and carries multiple
mutations in genes involved in self-antigen presentation and apoptosis [32]. It has been sug-
gested that lack of MHC diversity in devils contributes to the lack of host recognition of DFTD
cells [33,34], but despite their low diversity, experimental allogeneic skin transplants in devils
were recognized and rejected [35], and it has recently been shown that DFTD also down-regu-
lates expression of MHC genes [36].
As in CTVT and DFTD, immune evasion plays a key role in the two major settings of
human transmissible cancer mentioned above. Cancers transmitted during organ transplants
can survive because the recipients are immunosuppressed, and cancers transmitted from
mother to fetus are partially tolerated because the maternal cancer cells are half-matched to the
fetus—and in at least one case, the neoplastic cells from the mother that grew in the infant had
lost the MHC allele that was not shared with the infant [37]. Altogether, the data suggest that
MHC-based self–nonself rejection is highly important in preventing transmissible cancers.
Bivalves are invertebrates and do not have MHC or any other known histocompatibility sys-
tem, likely decreasing the barriers for evolution of transmissible cancer lineages. However,
there is some evidence for species-specific restriction of BTN lineages, as most known lineages
were derived from the original host species, and experimental transmission across species has
not been successful [38,39]. Only one example of cross-species transmission from a related spe-
cies has been observed, and in this case the original host speciesmay have developed resistance
to the lineage derived from it [23]. Currently, the mechanisms of these restrictions are
unknown. It may resemble self–nonself recognition systems in vertebrates or may be an inde-
pendent mechanism, as with the BHF gene involved in protecting tunicates from fusion with
foreign colonies and stem cell parasitism [40].
Cancer As an Infectious Organism
Clonal cancer lineages have spread far beyond their original hosts, replicating as asexual para-
sites that jump between individuals for decades (and evenmillennia, in the case of CTVT). It
is, in fact, difficult to determine whether to describe these cells as “infecting” or “engrafting”
their hosts, reflecting the fact that contagious cancers blur the lines between our normal defini-
tions of cancer and infectious disease. They even stretch our understanding of species, as the
living lineage of cells that form CTVThas not been a dog in 10,000 years. It is unlikely that can-
cer lineages can be considered to be new species, but regardless of terminology, their evolution
and replication strategies are clearly distinct from those of their hosts. These contagious cancer
lineages have developed a new infectious lifestyle separate from that of the organism from
which they arose, and their new interactions provide strong selective pressures, which can
affect evolution of both host and pathogen.
It is possible that the primary cancers that led to each of these transmissible cancer lineages
could have been induced by a conventional pathogen, but so far there is no evidence of this.
Some transmissible cancers may have been triggered by transposable elements; there is some
indication of the involvement of transposons in CTVT [3] and soft-shell clam-transmissible
neoplasia [19]. Regardless of their origin, all available evidence (including multiple genetic
markers and full cancer genome sequencing of CTVT and DFTD) leads to the conclusion that
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the cancer cells themselves have become a pathogen, able to spread from individual to
individual.
Conclusions
Transmissible cancers appear to be limited by twomain factors: immune recognition and phys-
ical barriers to the spread of cells. In a similar, but less extreme way, conventional cancers can
also be thought of as infectious cells that have their own evolutionary pressures and strategies
[41,42]. The evasion of immune recognition and the ability to metastasize have obvious paral-
lels in the two main challenges for transmissible cancers.
We know that cases of cancer transmission do occur in humans in the special settings of
organ transplant and maternal-to-fetal transfer. Transmission would not be likely to occur in
immunocompetent people, but we would predict that it is conceivable that certain types of can-
cer could spread from person to person within immunosuppressed HIV-1-positive
populations.
Currently, we know of transmissible cancers spreading through natural animal populations
in six species across vertebrate and invertebrate organisms and in both terrestrial and marine
ecosystems, and further study will likely uncover more examples. Despite recognition only
recently as bona fide infectious diseases, transmissible cancers may have been developing,
spreading, and producing a strong selective pressure on the evolution of organisms since the
beginning of multicellularity.
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